TRIPASS XR تري باس

 

intravenous clinical potential in the management of hypertensive urgencies and emergencies. Drugs.

1997;54:634.

Murphy MB et al. Fenoldopam—a selective peripheral dopamine-receptor agonist for the treatment of severe

hypertension. N EnglJ Med. 2001;345:1548.

Nichols AJ et al. The pharmacology of fenoldopam. Am J Hypertens. 1990;3:116S.

White WB, Halley SE. Comparative renal effects of intravenous administration of fenoldopam mesylate and

sodium nitroprusside in patients with severe hypertension. Arch Intern Med. 1989;149:870.

Oparil S et al. A new parenteral antihypertensive: consensus roundtable on the management of perioperative

hypertension and hypertensive crises. Am J Hypertens. 1999;12:653.

Bovet T et al. Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury

after cardiac surgery: a randomized clinical trial. JAMA. 2014;312:2244–2253.

Yakazu Y et al. Hemodynamic and sympathetic effects of fenoldopam and sodium nitroprusside. Acta

Anaesthesiol Scand. 2001;45:1176.

Everitt DE et al. Effect of intravenous fenoldopam on intraocular pressure in ocular hypertension. J Clin

Pharmacol. 1997;37:312.

Piltz JR et al. Fenoldopam, a selective dopamine-1 receptor agonist, raises intraocular pressure in males with

normal intraocular pressure. J Ocul Pharmacol Ther. 1998;14:203.

Cressman MD et al. Intravenous labetalol in the management of severe hypertension and hypertensive

emergencies. Am Heart J. 1984;107:980.

Wilson DJ et al. Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies. Am

J Med. 1983;75(4A):95.

Smith WB et al. Antihypertensive effectiveness of intravenous labetalol in accelerated hypertension.

Hypertension. 1983;5:579.

Dal Palu C et al. Intravenous labetalol in severe hypertension. Br J Clin Pharmacol. 1982;13(1, Suppl):97S.

Lebel M et al. Labetalol infusion in hypertensive emergencies. Clin Pharmacol Ther. 1985;37:615.

Vidt DG. Intravenous labetalol in the emergency treatment of hypertension. J Clin Hypertens. 1985;1:179.

Patel RV et al. Labetalol: response and safety in critically ill hemorrhagic stroke patients. Ann Pharmacother.

1993;27:180.

Kanto JH. Current status of labetalol, the first alpha-and beta-blocking agent. Int J Clin Pharmacol Ther Toxicol.

1985;23:617.

George RB et al. Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of

hypertensive patients with asthma and propranololsensitivity. Chest. 1985;88:815.

Walstad RA et al. Labetalol in the treatment of hypertension in patients with normal and impaired renal function.

Acta Med Scand Suppl. 1982;665:135.

Wood AJ et al. Elimination kinetics of labetalol in severe renal failure. Br J Clin Pharmacol. 1982;13(1,

Suppl):81S.

MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology pharmacokinetics, clinical uses and

adverse effects. Pharmacotherapy. 1983;3:193.

Eisalo A, Virta P. Treatment of hypertension in the elderly with labetalol. Acta Med Scand Suppl. 1982;665:129.

Abrams JH et al. Successful treatment of a monoamine oxidase inhibitor-tyramine hypertensive emergency with

intravenous labetalol. N EnglJ Med. 1985;313:52.

Navaratnarajah M, White DC. Labetalol and phaeochromocytoma. Br J Anaesth. 1984;56:1179.

Pearson RM, Havard CW. Intravenous labetalol in hypertensive patients treated with beta-adrenoceptor

blocking drugs. Br J Clin Pharmacol. 1976;3(4, Suppl 3):795.

Cumming AM et al. Intravenous labetalol in the treatment of severe hypertension. Br J Clin Pharmacol.

1982;13(1, Suppl):93S.

Flaherty JT et al. Comparison of intravenous nitroglycerin and sodium nitroprusside for treatment of acute

hypertension developing after coronary artery bypass surgery. Circulation. 1982;65:1072.

Chun G, Frishman WH. Rapid-acting parenteral antihypertensive agents. J Clin Pharmacol. 1990;30:195.

Francis GS. Vasodilators in the intensive care unit. Am Heart J. 1991;121:1875.

Rutledge J et al. Effect of intravenous enalaprilat in moderate and severe hypertension. Am J Cardiol.

1988;62:1062.

Evans RR et al. The effect of intravenous enalaprilat (MK-422) administration in patients with mild to moderate

essential hypertension. J Clin Pharmacol. 1987;27:415.

Hirschl MM et al. Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive

115.

116.

117.

118.

119.

120.

121.

122.

123.

124.

125.

126.

127.

128.

129.

130.

131.

132.

133.

134.

135.

136.

137.

138.

139.

140.

141.

crises. Arch Intern Med. 1995;155:2217.

White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors.

Pharmacotherapy. 1998;18:588.

Misra M et al. Evaluation of the efficacy, safety, and tolerability of intravenous enalaprilat in the treatment of

grade III essential hypertension in Indian patients. Indian Heart J. 2004;56:67.

DiPette DJ et al. Enalaprilat, an intravenous angiotensin-converting enzyme inhibitor, in hypertensive crises. Clin

Pharmacol Ther. 1985;38:199.

Haas CE, LeBlanc JM. Acute postoperative hypertension: a review of therapeutic options. Am J Health Syst

Pharm. 2004;61:1661.

Cheung DG et al. Acute pharmacokinetic and hemodynamic effects of intravenous bolus dosing of nicardipine.

Am Heart J. 1990;119:438.

[No authors listed]. Efficacy and safety of intravenous nicardipine in the control of postoperative hypertension.

IV Nicardipine Study Group. Chest. 1991;99:393.

Halpern NA et al. Nicardipine infusion for postoperative hypertension after surgery of the head and neck. Crit

Care Med. 1990;18:950.

Halpern NA et al. Postoperative hypertension: a prospective placebo controlled, randomized, double-blind trial

with intravenous nicardipine hydrochloride. Angiology. 1990;41:992.

Kaplan JA. Clinical considerations for the use of intravenous nicardipine in the treatment of postoperative

hypertension. Am Heart J. 1990;119:443.

Wallin JD et al. Intravenous nicardipine for treatment of severe hypertension. A double-blind, placebo-controlled

multicenter trial. Arch Intern Med. 1989;149:2662.

NeutelJM et al. A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of

severe hypertension. Am J Hypertens. 1994;7:623.

Qureshi AI et al. Treatment of acute hypertension in patients with intracerebral hemorrhage using American

Heart Association guidelines. Crit Care Med. 2006;34:1975.

Curran MP et al. Intravenous nicardipine: its use in the short-term treatment of hypertension and various other

indications. Drugs. 2006;66:1755.

Kwak YL et al. Comparison of the effects of nicardipine and sodium nitroprusside for control of increased blood

pressure after coronary artery bypass graft surgery. J Int Med Res. 2004;32:342.

Dorman T et al. Nicardipine versus nitroprusside for breakthrough hypertension following carotid

endarterectomy. J Clin Anesth. 2001;13:16.

Salerno DM et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter.

Am J Cardiol. 1989;63:1046.

Ellenbogen KA et al. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart

rate control during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll Cardiol. 1991;18:891.

Dougherty AH et al. Acute conversion of paroxysmal supraventricular tachycardia with intravenous diltiazem.

IV Diltiazem Study Group. Am J Cardiol. 1992;70:587.

Koh H et al. Clinical study of total intravenous anesthesia with droperidol, fentanyl, and ketamine: control of

intraoperative hypertension with diltiazem [article in Japanese]. Masui. 1991;40:1376.

Boylan JF et al. A comparison of diltiazem, esmolol, nifedipine, and nitroprusside therapy of post-CABG

hypertension. Can J Anaesth. 1990;37:S156.

Jaffe AS. Use of intravenous diltiazem in patients with acute coronary artery disease. Am J Cardiol.

1992;69:25B.

Fang ZY et al. Intravenous diltiazem versus nitroglycerin for silent and symptomatic myocardial ischemia in

unstable angina pectoris. Am J Cardiol. 1991;68:42C.

Onoyama K et al. Effect of drug infusion or a bolus injection of intravenous diltiazem on hypertensive crisis.